Table 1.
Patient | Ethnicity | Sex | Age, y | Tumor site | Normal tissue site | Pathology | Past therapy | Current therapy | TNMB | Clinical stage |
---|---|---|---|---|---|---|---|---|---|---|
1 | White | Female | 70 | Knee | Back | Nontransformed | XRT | Bexarotene, vorinostat | T3, N0, M0, B0 | IIB |
2 | White | Male | 67 | Upper arm | Abdomen | Granulomatous | NB-UVB | Bexarotene | T3, N2, M0, B0 | IIB |
3 | White | Male | 41 | Forearm | Abdomen | Nontransformed | Bexarotene | NB-UVB, topical bexarotene | T3, N0, M0, B0 | IIB |
4 | Black | Male | 35 | Scalp | Forearm | Large cell transformed | XRT, ECP bexarotene, romidepsin | Gemcitabine | T3, N2, M0, B2 | IVA1 |
5 | White | Female | 69 | Upper arm | Abdomen | Nontransformed | None | None | T3, N0, M0, B0 | IIB |
ECP, extracorporeal photopheresis; NB-UVB, narrow-band UV B; TNMB, tumor, node, metastasis, blood; XRT, local radiation therapy.